Drugs / LIB003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT03847974 | Feb 2019 → Apr 2020 | hyperlipoproteinemia | LIB Therapeutics LLC | Completed | No outcome recorded |
| Phase 2 | NCT03549260 | May → Nov 2018 | low density lipoprotein cholesterol, mild elevation of | LIB Therapeutics LLC | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03545438 Comparator | Oct 2017 → May 2018 | hyperlipidemia | LIB Therapeutics LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LIB003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03847974 ↗ |
| Route | Subcutaneous | “by SC injection” NCT03545438 ↗ |